

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A method of treating asthma in a subject comprising administering an anti-C5 antibody to a subject susceptible to or having asthma, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
2. (Currently amended) A method of ameliorating one or more symptoms associated with preventing asthma attacks comprising, before the onset of the one or more symptoms, prophylactically administering an anti-C5 antibody to a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
3. (Currently amended) A method of reducing the severity of an asthma attack comprising administering an anti-C5 antibody to a subject having an asthma attack, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
4. (Currently amended) A method of reducing airway obstruction in a subject comprising administering an anti-C5 antibody to the subject, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
5. (Currently amended) A method of increasing air flow in a subject comprising administering an anti-C5 antibody to the subject, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
6. (Currently amended) A method of reducing bronchial spasms in a subject comprising administering an anti-C5 antibody to the subject, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.

7. (Currently amended) A method of treating a chronic obstructive pulmonary disease in a subject comprising administering an anti-C5 antibody to the subject afflicted with a chronic obstructive pulmonary disease, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
8. (Currently amended) A method of reducing inflammation in a subject comprising administering an anti-C5 antibody to a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
9. (Currently amended) A method of treating a subject having established airway inflammation or a subject that has experienced previous asthmatic symptoms comprising administering an effective bronchial-dilating amount of an anti-C5 antibody, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.
10. (Original) A method as in claim 8 or 9 wherein the step of administering comprises administering the anti-C5 antibody during an asthma attack.
11. (Original) A method as in any of claims 1-9 wherein the subject is a human.
- 12-14. (Canceled)
15. (Currently amended) A method as in any of claims 1-9, wherein the anti-C5 antibody is selected from the group consisting of h5G1.1, h5G1.1-scFv and functional fragments of h5G1.1, wherein the functional fragment of h5G1.1 inhibit the conversion of complement component C5 into C5a and C5b.
16. (Previously presented) A method as in any of claims 1-9, wherein the anti-C5 antibody comprises at least one antibody-antigen binding site, said antibody exhibiting specific binding to the alpha chain of human complement component C5, wherein the antibody 1) inhibits complement

activation in a human body fluid; and 2) inhibits the binding of purified human complement component C5 to C5 convertase.

17. (Previously presented) A method as in any of claims 1-9, wherein the anti-C5 antibody is administered as an aerosol.

18. (Previously presented) A method as in any of claims 1-9, wherein the anti-C5 antibody is administered via a method selected from the group consisting of intravenous infusion by injection and subcutaneous injection.

19. (Canceled)

20. (Currently amended) A method for treating a subject having or susceptible to asthma comprising administering at least one member selected from the group consisting of steroids, anti-IgE antibodies, ~~anti IL-4 anti-IL-4~~ antibodies, anti-IL-5 antibodies, β 2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, ~~[[IL 13]] IL-13~~ antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors in combination with an anti-C5 antibody.

21. (Currently amended) A method of treating asthma comprising administering an anti-C5 antibody to the lungs of a subject without substantially reducing systemic complement activity in the subject, wherein the anti-C5 antibody inhibits the conversion of complement component C5 into C5a and C5b.

22-44. (Canceled)

45. (Previously presented) The method of claim 1, wherein the anti-C5 antibody is administered by nebulization.

46. (Previously presented) The method of claim 2, wherein the anti-C5 antibody is administered by nebulization.

47. (Previously presented) The method of claim 7, wherein the anti-C5 antibody is administered by nebulization.
48. (Previously presented) The method of claim 8, wherein the anti-C5 antibody is administered by nebulization.
49. (Previously presented) The method of claim 20, wherein the anti-C5 antibody is administered by nebulization.
50. (Previously presented) The method of claim 20, wherein the selected member is administered by nebulization.
51. (Currently amended) A method as in any of claims 1-9 wherein the anti-C5 antibody is administered in combination with a member selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, β 2 adreno receptor agonists, leukotriene inhibitors, 5 Lipoxygenase inhibitors, PDE inhibitors, CD23 antagonists, [[IL 13]] IL-13 antagonists, cytokine release inhibitors, histamine H1 receptor antagonists, anti-histamines and histamine release inhibitors.
- 52-58. (Canceled)
59. (New) A method as in claim 20 or 21, wherein the anti-C5 antibody is selected from the group consisting of h5G1.1, h5G1.1-scFv and functional fragments of h5G1.1, wherein the functional fragments of h5G1.1 inhibit the conversion of complement component C5 into C5a and C5b.
60. (New) A method as in claim 20 or 21, wherein the anti-C5 antibody comprises at least one antibody-antigen binding site, said antibody exhibiting specific binding to the alpha chain of human complement component C5, wherein the antibody 1) inhibits complement activation in a human body fluid; and 2) inhibits the binding of purified human complement component C5 to C5 convertase.